Morgan Stanley (NYSE:MS) analyst Matthew Harrison maintained a Hold rating on Alexion Pharmaceuticals (NASDAQ:ALXN) on Tuesday, setting a price target of $121, which is approximately 2.72% below the present share price of $124.38.
Harrison expects Alexion Pharmaceuticals to post earnings per share (EPS) of -$4.84 for the fourth quarter of 2020.
The current consensus among 13 TipRanks analysts is for a Moderate Buy rating of shares in Alexion Pharmaceuticals, with an average price target of $145.22.
The analysts price targets range from a high of $175 to a low of $114.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $1.44 billion and a net profit of $703.5 million. The company's market cap is $27.26 billion.
According to TipRanks.com, Morgan Stanley analyst Matthew Harrison is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.1% and a 62.50% success rate.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.